TWI637751B - Maesa japonica extracts and methods of use - Google Patents

Abstract

The present invention provides a method of using the extract of Maesa japonica to impart anti-aging benefits to the skin and/or to improve skin symptoms caused by aged or damaged skin.

Description

MAESA JAPONICA extract and method of use Related application

The present application claims priority to U.S. Patent Application Serial No. 13/324,150, filed on Dec. 13, 2011. This application also applies and claims its priority at the same time as the following application: PCT application filed on December 11, 2012 and designated by Qian Zheng as the first inventor entitled " Servissa japonica extracts and methods of use"PCT/US12/68858; and PCT Application No. PCT/US12, filed on December 11, 2012, and which listed Permanan Raaj Khusial as the first inventor entitled " Stephanotis jasminoides extracts and methods of use" /68866. The entire content of each of the above applications is hereby incorporated by reference in its entirety for all purposes.

SUMMARY OF THE INVENTION The present invention relates to a cosmetic composition for incorporation of an osmanthus extract and use thereof for reducing fine lines and wrinkles and improving skin by increasing epidermal thickness, reducing melanin production and/or stimulating collagen and/or hyaluronic acid production. The color tone makes the skin discolored and brightens and improves the overall appearance of the skin.

Consumers are increasingly focusing on cosmetics that treat, reduce or delay signs of aging or aging skin. The signs of positively aged or aged skin manifest themselves as wrinkles, wrinkles, sagging, dullness, discoloration, uneven tones, and/or rough skin. In addition, aged skin lacks strength and elasticity and is therefore brittle. The cosmetics industry is actively pursuing the use of reducing the age A product of the aging or aging skin and thereby providing a product that is resistant to wrinkles, rejuvenation and skin lightening (anti-aging compounds).

Human skin is broadly divided into two layers: providing an anatomical barrier to foreign elements and maintaining the surface epidermis of the internal environment, as well as providing nutrients and structural support to the epidermis. The epidermis consists primarily of keratinocytes and includes several sub-layers (from the innermost to the outer): the germinal/basal layer, the echinoderma, the granular layer, and the stratum corneum. Keratinocytes produced by mitosis of keratinocyte stem cells originate in the basal layer and then advance through the layer. As the cells move to the surface of the skin, they undergo a gradual differentiation that becomes non-nuclear, flattened, and highly keratinized. During this process, keratinocytes are highly organized. It forms a desmosome and a cell junction between keratin and lipid excretion to form an extracellular matrix that strengthens the skin. The keratinocytes eventually die and form the stratum corneum. In healthy skin, keratinocytes shed and were replaced continuously every 30 days.

Although keratinocytes are within the basal layer, they require melanin, a black ultraviolet light absorbing pigment from melanocytes. Melanocytes produce melanin in an organelle called melanin bodies and then transfer melanin bodies containing melanin to adjacent keratinocytes via their dendrites. Within each keratinocyte, the melanin bodies form a melanin cap that remains in the keratinocytes until the keratinocytes are detached from the skin. Melanin caps reduce UV-induced DNA damage to human epidermis and underlying cells and tissues. Melanin provides the skin with its color and therefore the intensity and number of skin colors, the size, the melanin content, the rate of formation of melanin-containing melanin bodies, the rate at which melanin-containing melanin bodies are transferred to keratinocytes, and melanin in keratinocytes The rate of degradation is related. For a more detailed background on melanin, see G. Costin and V. Hearing, "Human skin pigmentation: melanocytes modulate skin color in response to stress", The FASEB Journal, Vol. 21, pp. 976-994, April 2007, The disclosure of which is incorporated herein by reference in its entirety.

Hyaluronic acid (HA), a colloidal aminoglycan, also plays an important role in normal epidermis. The HA is a component of the extracellular matrix of the basal keratinocytes, thereby maintaining extracellular space and providing an opening and hydration structure for the passage of nutrients. HA can also be used as a free radical scavenger to promote the epidermis against solar radiation. HA can also be used as a modulator of keratinocyte proliferation and migration.

The dermis is located beneath the skin between the epidermis and the subcutaneous tissue. Since the epidermis has no blood vessels, the nutrients and oxygen of the cells of the epidermis depend on the blood vessels in the dermis. The dermis-epidermal junction (DEJ) is a specialized structure that maintains a close contact between the dense plate (i.e., the layer of the extracellular matrix on which the epithelium is located) and the connective tissue beneath the dermis. DEJ mainly consists of collagen and elastin and is structured as an interlocking finger protrusion from the epidermis and dermis, called the epidermal process. The epidermal process increases the surface area of the epidermis exposed to the dermis at DEJ to make the transfer of essential nutrients/oxygen more effective, and the two layers of the skin form strong bonds against mechanical stress (shear). In addition, the dermis is the thickest skin layer and contains the extracellular matrix of the skin, which is maintained by fibroblasts. Fibroblasts maintain the structural integrity of connective tissue by continuously secreting the extracellular matrix precursor. The main structural component of the dermis is called collagen protein. Collagen molecular bundles are stacked across the dermis, accounting for three-quarters of the dry weight of the skin. Collagen has a large tensile strength; and soft keratin, which is responsible for skin strength and elasticity. For a detailed background on collagen, see Lodish et al, Molecular Cell Biology, W. H. FREEMAN, New York, NY, 4th edition, 2000, the disclosure of which is incorporated herein in its entirety by reference.

Histological studies of the skin have shown that when aging occurs, the skin undergoes structural, functional, and metabolic changes in parallel with changes in aging and degeneration of other body organs. Although age and/or hormonal aging plays a significant role in skin aging, environmental stress (eg, sun exposure) may also initiate and/or accelerate skin aging due to overexposure in ultraviolet (UV) sunlight. In aged and/or aging skin, cells are added longer, less frequently, and/or decomposed faster. Specifically, when aging occurs, the production of collagen is reduced, and the degradation is accelerated, which is caused by the excessive production of collagenase (ie, collagen-decomposing protease). Place The lack of collagen produced can result in reduced skin strength and elasticity. Furthermore, due to the major component of collagen-based DEJ, DEJ flattens with aging to make the skin more brittle and more likely to shear. As the DEJ flattens, the amount of nutrients/oxygen transferred to the epidermis decreases, due to shrinkage of the surface area in contact with the epidermis. A decrease in HA in the extracellular matrix of the epidermis reduces the ability to transfer the epidermis with useful nutrients/oxygen to its cells. This ineffective nutrient/oxygen transport affects the keratinocytes and melanocytes of the epidermis. The rate of keratinocyte renewal is reduced and, therefore, the stratum corneum loses its ability to retain moisture and dehydrate the skin. In addition, the number of melanocytes is reduced and the remaining melanocytes can produce a greater amount of melanin, resulting in skin discoloration/hypigmentation and/or sunburn, "old age spots". At the surface of the skin, aged or aging skin can exhibit wrinkles and wrinkles, sagging, dullness, discoloration, uneven tones, rough skin and the like. In addition, aged or positively aged skin exhibits less strength and flexibility and is more brittle. Such signs of aging may be exacerbated by common agents (e.g., those indicated for use in the treatment of Parkinson's disease (i.e., Levodopa or menopause (i.e., hormonal therapy)).

A well-known product for anti-aging skin care is retinol, which has been shown to be effective in reducing visible signs of aging on the skin of the face. Retinol has side effects, including a tendency to cause skin irritation or a tendency to decompose upon exposure to oxygen or UV, thereby impairing its efficiency.

Osmanthus fragrans (also known as du jing shan or izo-senryo) is a perennial plant native to southern China, Vietnam and Japan. The plant has leaves which are hard paper or almost leather-like; elliptical, narrow elliptical lanceolate or oblong oval; 6 cm to 9 cm long and 3 cm to 5 cm wide; apex pointed, sharp or blunt; base circular Or rounded; rarely wedge-shaped; almost entirely or serrated on the top; 5 to 8 pairs of lateral veins; stem length 5 mm to 15 mm. Flowers are usually axillary racemes or panicles. Single flower sometimes gathers; flower length 3mm to 5mm; kidney-shaped bracteoles, with glandular streaks; calyx, imbricate, ovoid to spherical; bell-shaped corolla, white, 3mm to 4mm long, glandular Shaped and wide oval leaves. The osmanthus leaves have been used in traditional Chinese medicine to cure acne. Still need to solve the old A cosmetic composition that modifies signs, particularly wrinkles, lines, and the appearance of discolored areas. Accordingly, it is an object of the present invention to provide new compositions and methods of treating, ameliorating and/or preventing signs of aged or aging skin. Yet another object of the invention is to improve the overall appearance of aged or aged skin.

The above discussion is only to provide a better understanding of the nature of the problems faced by the technology and should not be construed as an admission of the prior art in any way. Prior art."

In accordance with the above objectives and others, it has been found that the extract of osmanthus fragrans is a beneficial agent for the synthesis of collagen, hyaluronic acid and melanin in the body and is therefore a sign of resistance to aging and discoloration in the skin.

SUMMARY OF THE INVENTION The present invention relates to a method for improving the aesthetic appearance of aged skin in need thereof by topically applying to the skin a composition in a cosmetically acceptable vehicle, the composition comprising an effective application to the skin. A beautifully improved amount of osmanthus extract. In one embodiment, the skin is sensitive to the skin. In yet another embodiment of the invention, the composition is topically applied to the skin at least once a day for at least one week.

In certain embodiments, aging can be due to age, hormonal, or environmental effects. In other embodiments, the improvement in aesthetics is selected from the group consisting of: (a) treating, reducing, and/or preventing fine lines or wrinkles; (b) reducing skin pore size; (c) improving skin thickness, fullness, and / or firmness; (d) improve skin suppleness and / or softness; (e) improve skin tone, brilliance and / or transparency; (f) improve procollagen and / or collagen production; (g) improve elastin (h) improve skin texture and/or promote skin rejuvenation; (i) improve skin barrier repair and/or function; (j) improve the appearance of skin contours; (k) restore skin shine and/or brightness (l) replenish essential nutrients and/or ingredients in the skin; (m) improve the appearance of the skin attenuated by aging and/or menopause; (n) improve skin moistness and/or hydration; (o) increase and / or Prevent loss of skin elasticity and/or rebound; (p) treat, reduce and/or prevent under the skin (q) treating, reducing and/or preventing skin discoloration; and (r) any combination thereof. In other embodiments of the invention, skin improvement may be due to increased collagen synthesis, increased hyaluronic acid synthesis, increased epidermal thickness, decreased melanin synthesis, or any combination thereof.

In still another embodiment of the present invention, the extract may be present in an amount of from about 0.0001% by weight to about 90% by weight based on the total weight of the composition, and in yet another embodiment, may be about 0.01% by weight based on the total weight of the composition. It is present in an amount of up to about 10% by weight. In certain embodiments, the osmanthus plant extract may be derived from the flower of a osmanthus plant.

Another embodiment of the present invention relates to a method for improving barrier function and vitality of the skin by topically applying to the skin a composition for a cosmetically acceptable vehicle, the composition comprising an effective A sweet-scented osmanthus extract that increases collagen synthesis, increases hyaluronic acid synthesis, increases epidermal thickness, reduces melanin synthesis, or any combination thereof. In a particular embodiment of this method, the extract is derived from the flower of the osmanthus flower. In other embodiments of the method, the plant extract is present in an amount from about 0.0001 wt% to about 90 wt%, based on the total weight of the composition, and in still other embodiments, the botanical extract is based on the total composition It is present in an amount of from about 0.01% by weight to about 10% by weight.

A further embodiment of the method of the present invention relates to the treatment of wrinkles, fine lines or sagging skin by topically applying to the skin a composition for a cosmetically acceptable vehicle, the composition comprising an effective A sweet-scented osmanthus extract that treats the amount of skin needed.

A method of making a skin light in need is another embodiment of the present invention. The method involves topically applying to a skin in need thereof a brightening composition in a cosmetically acceptable vehicle, the composition comprising an extract of osmanthus fragrans in an amount effective to achieve a luminous benefit. In other embodiments of this method, the plant extract is present in an amount from about 0.01% to about 10% by weight, based on the total weight of the composition.

In certain embodiments, the luminous benefit can be selected from the group consisting of: (a) bleaching hyperpigmented hair, skin, lips, and/or nails; (b) reducing age spots; (c) making skin (d) improving the appearance of the dark circles under the eyes; (e) treating black spot, chloasma, freckles, scars after burns and hyperpigmentation after injury; (f) bleaching the scalp, legs, Hair on the face and other areas where bleaching and color reduction are desired; (g) bleaching nail staining; and (h) combinations thereof. The brightening benefit may be due to reduced melanin synthesis, and in certain embodiments, the melanin synthesis reduction may be about 20-100%, and in other embodiments may be about 40-100%.

A further embodiment relates to a method of treating skin by topically applying to the skin area in need thereof an effective amount of a skin biomarker-regulating osmanthus extract, wherein the skin biomarker selected from the group consisting of: Analysis of the amount of change to determine the ability of the extract of Osmanthus fragrans to regulate skin biomarkers: thickening of the epidermis, total collagen, procollagen, and hyaluronic acid in skin cells and/or pre-differentiation precursors of skin cells in contact with osmanthus extract protein.

These and other aspects of the present invention will be better understood from the following detailed description and drawings.

Figure 1 is an HPLC overview of the extract of Osmanthus fragrans.

The detailed embodiments of the present invention are disclosed herein; however, it is understood that the disclosed embodiments are only illustrative of the invention, and the invention may be embodied in various forms. In addition, each of the examples given in connection with the various embodiments of the invention is intended to be illustrative and not restrictive. In addition, the figures are not necessarily to scale, and some features may be exaggerated to show the details of the embodiments. In addition, any measurement, description, and the like in the figures are intended to be illustrative and not limiting. Therefore, the specific structural and functional details disclosed herein are not to be construed as limiting, but as a representative basis of the teachings of those skilled in the art.

Successful recovery of young skin must address several key issues, including: Fibrillation Cell and keratinocyte viability, cell-cell adhesion in the epidermis and dermis, cell nutrition to the epidermis, cell-cell anchorage and adhesion between keratinocytes, communication between the dermis and epidermis, overproduction of collagenase, Collagen replacement and mechanical properties of the skin. The present invention addresses these critical issues via the use of cosmetic compositions incorporating osmanthus extract. In particular, the compositions of the present invention can be used to reduce fine lines and wrinkles, improve skin tone and reduce discoloration and improve the overall appearance of the skin. The osmanthus extract can increase epidermal thickness, reduce melanin synthesis, stimulate collagen synthesis, stimulate hyaluronic acid synthesis, and/or promote any combination thereof.

The present invention provides compositions for topical administration comprising an effective amount of osmanthus extract to treat, reverse, ameliorate and/or prevent signs of skin damage or skin aging. These benefits include, but are not limited to, the following: (a) treating, reducing and/or preventing fine lines or wrinkles, (b) reducing skin pore size, and (c) improving skin thickness, fullness and/or firmness (d) improving skin suppleness and/or softness; (e) improving skin tone, brilliance and/or transparency; (f) improving procollagen and/or collagen production; (g) improving elastin maintenance and remodeling (h) improve skin texture and / or promote skin rejuvenation; (i) improve skin barrier repair and / or function; (j) improve the appearance of skin contours; (k) restore skin shine and / or brightness; (l) supplement Essential nutrients and/or ingredients in the skin; (m) improving the appearance of the skin attenuated by aging and/or menopause; (n) improving skin moisturization and/or hydration; (o) increasing and/or preventing loss of skin elasticity And/or rebound flexibility; (p) treating, reducing and/or preventing sagging of the skin; and/or (q) treating, reducing and/or preventing discoloration of the skin.

In fact, the compositions of the invention can be applied to the skin in need of treatment. That is, suffering from any loss or loss of any of the above attributes or otherwise would benefit from any of the above-described skin attributes.

In another embodiment, the composition incorporating the osmanthus extract is used to brighten, ie, reduce, pigmentation of the hair, skin, lips and/or nails to achieve the following luminous benefits: (a) bleaching hyperpigmented hair, (b) reducing age spots; (c) making skin discoloration uniform or optimal; (d) improving the appearance of the underlying dark circles; (e) treating black spot, chloasma, freckles , post-burn scars and hyperpigmentation after injury; (f) bleaching of scalp, legs, face and other areas of bleaching and color reduction; and/or (g) bleaching nail staining.

In one embodiment, the composition is intended for use as a non-therapeutic treatment. In another embodiment, the composition is intended to be wiped, poured, sprayed or sprayed onto the human body, introduced into the human body, or otherwise applied to the human body for cleaning, beautification, promotion, according to the US FD&C Act, sec. 201(i). An object that appeals or changes its appearance.

In fact, the compositions of the invention can be applied to the skin in need of treatment. That is, suffering from any loss or loss of any of the above attributes or otherwise would benefit from any of the above-described skin attributes.

Unless otherwise stated, all terms used herein are intended to have their ordinary meaning.

The term "activity amount" means no diluent, solvent, carrier, filler or any The amount of osmanthus extract under other ingredients. An "effective amount" ("amount effective" or "effective amount") is used to provide a specific indication of aging (ie, clinically measurable in the administration or administration of a specific performance sufficient to provide aging) The clinically measurable improvement in the "activity amount" of the extract required for the improvement of the undesired characteristics associated with aging.

The term "person in need" as used herein refers to an individual who has undesired skin symptoms due to aging, undesirable characteristics (such as wrinkles and wrinkles, sagging, dullness, discoloration, uneven color tone, rough skin, etc.) or does not exist. Individuals selected to reduce the effects of aging (ie, preventive or prophylactic) under significant and undesirable skin conditions.

The term "consisting essentially of" is used herein to mean that the invention is limited to the specified materials or steps and that they do not significantly affect the basic and novel characteristics of the claimed invention.

"Cosmetically acceptable" means that a particular component is generally considered safe and non-toxic at the dosage employed.

The term "discoloration" as used herein includes disperse pigmentation and speckle pigmentation. Disperse pigmentation is a different uniform area than dark pigment and can appear as brown spots or freckles on the skin and can include sun-spotted ticks, dark spots on the skin caused by aging and the sun, also known as "life spots", "Old age freckles" or "old age spots" or freckles, freckles. Spotted pigmentation systems are larger in size and shape than discolored pigmentation and more irregular dark spots and may include chloasma, dark spots such as those caused by hormones (ie, due to pregnancy, birth control pills or estrogen replacement therapy). Symptoms such as illness and skin discoloration. Discoloration can be due to external factors including, but not limited to, UV-R, skin tanning and photoaging, drugs and/or chemicals, or internal factors including, but not limited to, heredity, hormonal effects, and/or inflammation. In certain embodiments of the invention, discoloration may not include hyperpigmentation due to inflammation due to acne or dermatitis.

Skin elasticity refers to the ability of the skin to regain its original shape and size after deformation. Flexibility and resilience. Skin elasticity can be evaluated by a pinch test which can be deformed by stretching or squeezing the skin.

The term "essential oil" as used herein refers to a volatile etheric moiety obtained from a plant or plant part by a physical separation process such as distillation or chromatographic separation. Essential oils often contain a cockroach such as a cockroach and have the taste and aroma of the plant from which they are extracted.

The term "bright" is used herein to mean any measurable reduction in skin color/pigmentation of the hair, skin, lips and/or nails, such as reduction of visible to the naked eye, in the treatment of individual skin and treatments containing osmanthus extract. Occurs after contact. By way of example, this may mean that the skin is discolored or optimized (ie, bleaching age spots, freckles, etc.) to reduce or eliminate color differences between the color-changing skin and the surrounding skin; and/or to cause normal pigmentation/skin color in the individual. overall bright, even skin lightening. The term reducing pigmentation, lightening, bleaching or color reduction is used interchangeably herein. Without wishing to be bound by a particular theory, Applicants believe that the herbal extract of the present invention achieves this luminous effect by impairing melanin synthesis, thereby reducing melanin production. The term "reducing melanin production" is used herein to mean a detectable decrease in the amount of melanin synthesized by melanocytes exposed to the inhibitory compound compared to the amount of melanin synthesized under the extract of osmanthus fragrans. The term "reduction" as used herein with respect to melanin means to completely prevent, control secretion or to some extent reduce melanin formation. In one embodiment, the term "reduced" means that the amount of melanin synthesized thereby is reduced by from about 10% to about 100%. In one embodiment, the term "reduced" means that the amount of melanin synthesized is reduced by from about 25% to about 100%. In one embodiment, the term "reduced" means that the amount of melanin synthesized is reduced by from about 35% to about 100%. In one embodiment, the term "reduced" means that the amount of melanin synthesized is reduced by from about 40% to about 100%. The terms reduction, alleviation, reduction, suppression, and inhibition are intended to be used interchangeably when used with respect to melanin production. This reduction in melanin production can be assessed subjectively or by analysis using, for example, but not limited to, in vitro, ex vivo, animal models, and/or clinical models known to those skilled in the art. For example, methods known to those skilled in the art (including, but not limited to, human melanocyte culture, melanoma culture (see Example 3 below and U.S. Patent No. 7,189,419, the disclosure of which is incorporated herein by reference in entirety Incorporated herein, HRM2 hairless mouse model (see Chung et al. "Evaluation of in vitro and in vivo anti-melanogenic activity of a newly synthesized strong tyrosinase inhibitor (E)-3-(2,4 dihydroxybenzylidene) Pyrrolidine-2,5-dione(3-DBP),"Biochim Biophys Acta. July 2012; 1820(7): 962-9, the entire contents of which are hereby incorporated by reference for all purposes), Zebra Fish model (see Choi, TY; Kim, JH; Ko, DH; Kim, CH; Hwang, JS; Ahn, S.; Kim, SY; Kim, CD; Lee, JH; Yoon, TJZebrafish as a new model for phenotype -based screening of melanogenic regulatory compounds. Pigment Cell Res. 2007,20,120-127, in its entirety for all purposes begin incorporated herein by reference) and MelanoDerm ^TM skin model (the MatTek Corporation, Ashland, MA)) established melanoma The synthesis is reduced.

As used herein, "prevention" and related terms (such as "prevent" or "preventing") mean the following benefits for skin that has not been affected by symptoms: for avoiding, delaying, confronting, minimizing or reducing One or more recurrence/onset of undesired characteristics associated with skin symptoms to be prevented. Such prophylactic benefits include, for example, delaying the development and/or recurrence of symptoms, or reducing one or more symptoms (if their development is ultimately The duration, severity or intensity of the undesired characteristics associated with it. The use of the term "prevention" is not intended to imply that all individuals in the individual group of the cosmetic composition will never suffer from cosmetic or dermatological symptoms or damage. , effects or symptoms invade or develop such conditions, but the individual population will present a reduction in cosmetic or dermatological damage, effects or symptoms. For example, many influenza vaccines are not prevented when they are administered vaccines. 100% effective. Preventing aging means providing the unaffected skin with the benefit of avoiding, delaying, combating or minimizing one or more undesirable characteristics associated with aging, such as reducing the lines and wrinkles that ultimately form in the treated area, Drooping, dull, discolored, uneven tones, rough The extent of skin and/or fragility.

The term "skin" as used herein includes skin on or in the face, mouth, neck, chest, back, arms, hands, legs and scalp. "Thin skin" is intended to include skin that is thinned by ageing, menopause or light damage.

As used herein, "treatment" and related terms (eg "treat" or "treating") refers to eradication, alleviation, amelioration or reversal of one or more undesirable characteristics associated with the skin condition being treated. To cause the consumer to notice an improvement in the appearance of the skin or other therapeutic benefit with regard to the symptoms. Treatment of skin aging or damage means eradicating, mitigating, ameliorating or reversing one or more undesirable characteristics associated with aging. Undesirable characteristics associated with aged skin For example, wrinkles and wrinkles, sagging, dullness, uneven hue, discoloration, rough skin, etc. Undesirable features associated with discoloration, such as age spots, freckles, melasma, dark spots, post-inflammatory hyperpigmentation The therapeutic benefits include, for example, reducing the appearance of wrinkles, wrinkles and/or sagging, restoring the skin, making the skin tone uniform, softening the skin and/or brightening the color. The compositions and methods of the present invention are suitable for treating many Body area (including but not limited to face, forehead, lips, neck, arms, hands, legs, knees, feet, chest, back, groin, buttocks, etc.) Dermatological symptoms of the skin. In another embodiment, the composition is applied to the face.

The term "wrinkle" or "wrinkle" refers to both fine wrinkles and coarse wrinkles. Fine wrinkles or fine lines refer to superficial lines and wrinkles on the surface of the skin. Rough wrinkles are deep wrinkles, especially deep lines/wrinkles on the face and around the eyes, including expression lines such as frown lines and wrinkles, forehead lines and wrinkles, crow's feet and wrinkles, ritual and puppet lines and wrinkles. Forehead lines and wrinkles refer to superficial lines and/or deep wrinkles on the forehead skin. Crow's feet and wrinkles refer to superficial and/or deep wrinkles on the skin surrounding the area of the eye. Puppet lines and wrinkles are shallow lines and/or deep wrinkles on the skin around the mouth. Wrinkles can be assessed for the number, length and depth of the lines.

All percentages are based on the total weight of the composition unless otherwise indicated.

Cosmetic composition

The cosmetic composition used in the method of the present invention comprises a plant component derived from a osmanthus plant. The osmanthus plant may be in any form including, but not limited to, whole plants, dried plants, ground plants or parts thereof (including, but not limited to, seeds, needles, leaves, roots, bark, spherules, stems , rhizomes, callus cells, protoplasts, organs and organ systems and meristems, or extracts, dried extracts, synthetic extracts or components found in or isolated from parts of plants and/or plants and/or Or ingredients, or extracts derived directly from plants or from plants, or any combination thereof. In one embodiment, the cosmetic composition used in the plant component of the invention is derived directly from the osmanthus plant. The plant component can be in pure form, semi-pure form or unpurified form. The osmanthus plant component can be in the form of a liquid, semi-solid or solid consistency. In one embodiment, the plant component can be an essential oil.

In one embodiment, the raw material is collected from the stems, leaves, and/or flowers of the osmanthus plant, and in certain embodiments, the raw material is obtained primarily or exclusively from the flowers of the osmanthus flower. In certain embodiments, the raw materials collected from the osmanthus plants are ground to a small particle size. In addition, the raw materials can be dried to reduce the water content. The raw materials can be air dried, oven dried, rotary evaporated under vacuum, lyophilized, or dried by any other suitable method known in the art.

The osmanthus extract can be obtained by distilling the raw material with a stripping agent. The stripping agent can be a liquid that is miscible, immiscible or partially miscible with the desired extract of osmanthus. Suitable stripping agents include, but are not limited to, the following: water; alcohols (eg, methanol, ethanol, propanol, butanol, and the like); glycols; ethers (eg, diethyl ether, dipropyl ether, and the like); esters (eg, acetic acid) Butyl ester, ethyl acetate and the like; ketones (such as acetone, ethyl methyl ketone and the like); dimethyl hydrazine; acetonitrile; other organic solvents; In one embodiment, the stripper is immiscible with the desired extract of osmanthus. The osmanthus extract can be collected by phase separation from the stripper. It is believed that the stripping agent increases the overall vapor pressure of the distillation system to obtain the osmanthus extract and thereby lowers the boiling point of the desired product, the osmanthus extract.

In other embodiments, the osmanthus plant component may be in the form of an extract obtained by solvent extraction, in one embodiment by organic solvent extraction. In short, organic dissolution The agent extraction method involves washing and extracting a raw material using an organic solvent, which may be a whole plant or ground to a small particle size. Non-limiting examples of organic solvents include methanol, ethanol, isopropanol, dichloromethane, chloroform, hexane, xylene, and petroleum ether. Organic solvent extraction can be performed using an extractor, as is well known in the art. The raw material can be slowly pushed into the extraction machine by the pusher. An organic solvent (eg, ethanol) can be added to the machine via a solvent inlet at the top of the waste discharge outlet. Due to gravity and equilibrium differences, the solvent flows forward to the raw material inlet, soaking the materials and flowing out from the opposite side of the solvent inlet. Since the plant material and the solvent move in opposite directions to each other, the plant material is always immersed in the solution containing the low concentration extract. Due to the equilibrium result, a high yield of plant ingredients can be achieved by continuously extracting plant material in a low concentration solution.

The extraction time suitable for extracting the components of the osmanthus plant is typically between about 1-10 hours, more often between about 2-8 hours in one embodiment, and most often between about 3-6 hours in another embodiment. The extraction temperature is between about 30 ° C and 100 ° C, in one embodiment between about 40 ° C and 70 ° C, and more often between about 50 ° C and 60 ° C in one embodiment. The collected extract is then finely filtered to remove debris and it can be used directly or concentrated by, for example, distillation of the solvent or by other conventional treatments. The solution of the extract active can be rotated or vacuum dried under vacuum. Typical extracts have an active level of greater than about 25%, in one embodiment greater than 50%, and the extract may also be provided as an essential oil or as a concentrate having a semi-solid or solid consistency.

Similarly, aqueous-organic solvent extraction involves the collection of raw materials from the osmanthus plants, which may be whole plants or ground to small particle sizes. Depending on the solubility and stability of the desired extract under acidic or basic (base) conditions, the ground plant material is immersed in an acidic or basic aqueous solution. For extraction under acidic conditions, an acid such as hydrochloric acid or sulfuric acid is added to the water at a concentration of, for example, about 3% (w/v). For the extraction under alkaline conditions, a base such as sodium hydroxide or sodium carbonate is added to the water. The extraction time and temperature of the extraction are generally similar to those used in the above organic solvent extraction methods.

The extract was then collected and finely filtered to remove debris. Depending on the acidity or basicity of the collected extract, an alkaline agent (for example, ammonia) or an acidulant (for example, sulfuric acid) may be added to the extract to neutralize the solution by adjusting the pH. The aqueous extract can be used directly, in concentrated or dried form. Alternatively, an organic solvent can then be added to the neutralizing solution to transfer the extract from the aqueous phase to the organic phase. Examples of such organic solvents include, but are not limited to, ethanol, isopropanol, butanol, pentanol, hexanol, and xylene. The extract comprising the transfer extract active dissolved in an organic solvent can be used directly in the form of an essential oil or concentrate, or dried by several different means, such as air drying, oven drying, rotary evaporation under vacuum or lyophilization to a semisolid. Or solid consistency.

It should also be noted that different plants containing different ingredients can be mixed and extracted with osmanthus. In one embodiment, the process of mixed extraction is used to extract plants which contain ingredients similar to those of osmanthus fragrans in a solvent for extraction (e.g., ethanol). The mixture of extracts can be concentrated and stored in a suitable solvent.

In another embodiment, the osmanthus extract used herein also includes a "synthetic" extract, i.e., various combinations of known osmanthus plant components and/or ingredients that are combined to substantially mimic the natural source of osmanthus Composition and/or activity of plant extracts. In one embodiment, the synthetic extract has substantially the same number of active components as the native osmanthus plant material. The consistency of the active substance between the synthetic extract and the natural osmanthus plant material can also be described in terms of "common percentage". The synthetic extract has a chemical composition of about 50% or greater with the chemical composition of the plant or natural extract. In other words, the synthetic extract has about 50% or more of the active ingredient found in the plant or natural extract. In one embodiment, the chemical composition of the synthetic extract has a commonality of about 70% or greater with the chemical composition of the plant or natural extract. Most preferably, the synthetic extract has a chemical composition of about 90% or greater with the chemical composition of the plant or natural extract.

The compositions of the present invention may be formulated for topical application in a variety of forms and will comprise from about 0.0001% to about 90% by weight of the osmanthus extract, and in one embodiment will comprise From about 0.0005 wt% to about 25 wt%, in one embodiment from about 0.001 wt% to about 10 wt%. In a more preferred range, the composition may comprise between about 0.005%, 0.01%, 0.05%, 0.1%, 0.25%, 0.5%, 0.75%, or 1% by weight of the total composition. Osmanthus fragrans extract in the range of 5% by weight, 7.5% by weight or 10% by weight. The composition will comprise an effective amount of osmanthus extract, which means an amount sufficient to reduce and/or inhibit the appearance of signs of aging or damage in the area when applied topically in a given area of the skin. The above amount refers to the "activity amount" of the extract of Osmanthus fragrans.

According to the present invention, compositions comprising components of osmanthus plants include, but are not limited to, topical formulations, antioxidants, anti-inflammatory agents, sunscreens, cosmetics (including dressings), personal care products (eg, antiperspirant) Agent or deodorant for controlling body odor), external application agent, skin penetration enhancer and the like. Also in accordance with the present invention, such compositions comprising osmanthus plant components and additional ingredients can be formulated in a variety of product forms. The compositions can be prepared in a target delivery system (e.g., creams, lotions, gels, toners, serums, transdermal patches, and the like), especially for topical administration. Target delivery and/or penetration enhancement can also be achieved by iontophoresis.

The invention further provides compositions comprising a plant component of osmanthus fragrans, which in one embodiment are used in the methods of the invention for topical administration for target delivery. The method of the invention is suitable for all skin types, such as sensitive, normal, oily or combination skin. In a particular embodiment, in one embodiment, the composition can be applied to a sensitive skin or hair type. Applying the composition to the skin or hair for aesthetics sufficient to improve skin-related symptoms, including undesirable features associated with aging, such as wrinkles, wrinkles, sagging, dullness, uneven hue, discoloration, rough skin, and the like period. The composition can be administered topically, once or twice daily, and once per day in one embodiment. Daily administration can be administered for a period of 1 week, 2 weeks, 4 weeks or longer.

The compositions may be formulated as liposomes, which may contain other additives or substances, and/or which may be modified to more specifically arrive or remain at the site after administration. this The compositions of the present invention can improve aesthetics by treating at least one skin aging or damaging undesirable undesirable characteristics.

Another embodiment of the method of the invention encompasses a composition comprising a cosmetically or dermatologically acceptable formulation adapted to contact live animal tissue, including human tissue, without substantial disadvantage to the user. Physiological effects. The compositions encompassed by the present invention may be provided in any cosmetically and/or dermatologically suitable form (in one embodiment, such as a lotion or cream), but also in an anhydrous or aqueous base, and in the form of a sprayable liquid. Other suitable cosmetic product forms of the compositions used in the present invention include, for example, lotions, creams, balms, glazes, lotions, masks, serums, toners, ointments, mousses, patches, pomades , solution, spray, wax-based sticks or wet wipes. In one embodiment, the composition is not a mask. Additionally, the compositions may include one or more compatible cosmetically acceptable adjuvants commonly used by those skilled in the art, such as coloring agents, fragrances, emollients, wetting agents, preservatives, vitamins, chelating agents. Mixtures, thickeners, perilla oil or perilla seed oil (WO 01/66067, "Method of Treating a Skin Condition", all of which is incorporated herein for all purposes) and the like, as well as other botanicals, such as aloe vera, Chamomile and the like, and as further explained below.

The invention also encompasses transdermal delivery modes, such as patches and the like, with or without a suitable penetration enhancer. The method of the present invention and the manner in which the osmanthus component can be effectively administered in a transdermal system. Thus, transdermal means of delivering a composition or formulation to a skin (often having a penetration enhancing composition) is a transdermal patch or a similar device as is known and described in the art. Transdermal patches are designed to deliver an effective amount of the compound across the skin of the user. Transdermal patches typically involve a liquid, gel, solid matrix or pressure sensitive adhesive carrier into which the osmanthus extract can be incorporated. Patch formulations and formulations are well known in the art. See, for example, "Dermatological and Transdermal Formulations" (Drugs and the Pharmaceutical Sciences, vol. 119), Kenneth A Walters (editor), Marcel Dekker, and "Transdermal Drug Delivery" (Drugs & the Pharmaceutical Sciences), Richard H. Guy (ed.), Jonathan Hadgraft (editor), original revision 2, Marcel Dekker and "Mechanisms of Transdermal Drug Delivery" (Drugs & the Pharmaceutical Sciences, Volume 83), by Russell O. Edited by Potts and Richard H. Guy (1997). Examples of such devices are disclosed in U.S. Patent Nos. 5,146,846, 5,223,262, 4,820, 724, 4, 379, 454, and 4, 956, 171, and U.S. Patent Publication No. US Pat. This description is incorporated herein by reference. The transdermal mode of storing and delivering the composition onto the skin (including hair) and forming the active composition is convenient and well suited for the purposes of the examples of the present invention. In another method, administration is via a sustained release vehicle, vehicle or diluent (eg, topical sustained release patch). In one embodiment, when a topical patch is used, the patch is applied to the desired area for an extended period of time. In one embodiment, the extended period of time is greater than one hour, and in one embodiment, the extended period of time is overnight, ie, while the user is asleep. Additionally, the transdermal patch can be formulated to provide a prolonged benefit for a period of about 1-7 days, in one embodiment about 2 to 7 days, and in one embodiment about 3-7 days. Such extended wear patches may be particularly well suited for treating, ameliorating and/or preventing discoloration. In addition, because many compounds that make skin pigmentation/color brightening are UV sensitive, transdermal patches can be used to allow continued treatment while the wearer is exposed to sunlight, thereby providing greater freedom to the wearer. In such cases, in one embodiment, the exterior of the transdermal patch is flesh-colored, and in one embodiment, the patch should closely match the skin color of the wearer to provide discreet treatment.

The topical composition can include one or more cosmetically acceptable vehicles. The vehicles may take any form known in the art to be suitable for application to the skin and may include water (eg, deionized water); vegetable oils; mineral oils; esters such as octyl palmitate, isopropyl myristate and palm. Isopropyl acrylate; ethers such as dioctyl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol and biphenyl Alcohol; isoparaffin, such as isooctane, isododecane and isohexadecane; polyfluorene oxide, such as cyclomethicone, dimethylpolyoxane, dimethicone cross-polymerization , polyoxyalkylene and derivatives thereof, in one embodiment organically modified derivatives; hydrocarbon oils, such as mineral oils, petrolatum, isodecane and polyisobutylene; polyols such as propylene glycol, glycerin, butyl Glycols, pentanediols and hexanediols; waxes, such as beeswax and vegetable waxes; or any combination or mixture of the foregoing.

The vehicle may comprise an aqueous phase, an oil phase, an alcohol, a polyoxo phase or a mixture thereof. Cosmetically acceptable vehicles may also contain an emulsion. Non-limiting examples of suitable emulsions include water-in-oil emulsions, oil-in-water emulsions, water-in-oil emulsions, water-in-water emulsions, water-in-wax emulsions, water-oil-water triple emulsions or creams, condensation An analog of the appearance of a gel or microemulsion. The emulsion may include an emulsifier such as a nonionic, anionic or amphoteric surfactant.

In one embodiment, the oil phase of the emulsion has one or more organic compounds, including emollients; wetting agents (eg, butylene glycol, propylene glycol, methyl glucosamine-20, and glycerin); other waters are dispersible Or a water soluble component, including a thickening agent, such as veegum or hydroxyalkyl cellulose; a gelling agent, such as high MW polyacrylic acid, namely CARBOPOL 934; and mixtures thereof. The emulsion may have one or more emulsifiers capable of emulsifying the various components present in the composition.

Suitable compounds for use in the oil phase include, but are not limited to, vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dioctyl ether; fatty alcohols such as hexadecane Alcohols, stearyl alcohols and behenyl alcohols; isoparaffins such as isooctane, isododecane and isohexadecane; polyoxygenated oils such as dimethylpolyoxane, cyclic polyoxane and polyfluorene Oxane; hydrocarbon oils such as mineral oils, petrolatum, isoicosane and polyisobutylene; natural or synthetic waxes; and the like. Suitable hydrophobic hydrocarbon oils may be saturated or unsaturated, have aliphatic character and are linear or branched or contain alicyclic or aromatic rings. The oil-containing phase may consist of a single oil or a mixture of different oils.

Hydrocarbon oils include those having from 6 to 20 carbon atoms, and in one embodiment from 10 to 16 carbon atoms. Representative hydrocarbons include decane, dodecane, tetradecane, tridecane, and _C8-20 isoparaffins. Paraffins are commercially available from Exxon under the trademark ISOPARS and are commercially available from Permethyl Corporation. Further, a C _8-20 paraffin (for example, a C ₁₂ isoalkane (isododecane) manufactured by Permethyl Corporation under the trade name Permethyl 99A ^TM ) is also suitable. Such as isohexadecane (trade name Permethyl®) and other commercially available C ₁₆ isoparaffins are also suitable. Examples of preferred volatile hydrocarbons include polydecane, for example, isododecane and isodecane, which include, for example, Permethyl-99A (Presperse) and C ₇ -C ₈ to C ₁₂ -C ₁₅ isoparaffins. For example, the Isopar series available from Exxon Chemicals. A representative hydrocarbon solvent is isododecane.

The oil phase may comprise one or more waxes including, for example, rice bran wax, carnauba wax, small crown coconut wax, candelilla wax, montan wax, sugar cane wax, ozokerite wax, polyethylene wax, Fischer- Tropsch wax, beeswax, microcrystalline wax, polyoxynized wax, fluorinated wax, and any combination thereof.

Non-limiting emulsifiers include emulsifying waxes, emulsified polyhydric alcohols, polyether polyols, polyethers, monoesters or diesters of polyhydric alcohols, ethylene glycol monostearate, glyceryl monostearate, glycerol Fatty acid esters, emulsifiers containing polyoxyxides, soy sterols, fatty alcohols (e.g., cetyl alcohol), acrylates, fatty acids (e.g., stearic acid), fatty acid salts, and mixtures thereof. Preferred emulsifiers include soy sterol, cetyl alcohol, stearic acid, emulsifying wax, acrylate, polyoxymethane-containing emulsifier, and mixtures thereof. Other specific emulsifiers useful in the compositions of the present invention include, but are not limited to, one or more of the following (to name a few): C _10-30 alkyl acrylate crosspolymer; dimethyl fluorene Oxylkane PEG-7 isostearate, acrylamide copolymer; mineral oil; sorbitan ester; polyglyceryl-3-diisostearate; sorbitan monostearate, sorbitan Tristearate, sorbitan sesquioleate, sorbitan monooleate; glycerol esters, such as glycerol monostearate and glycerol monooleate; polyoxyethylene phenol For example, polyoxyethylene octylphenol and polyoxyethylene nonylphenol; polyoxyethylene ethers such as polyoxyethylene cetyl ether and polyoxyethylene stearyl ether; polyoxyethylene glycol ester; polyoxyethylene sorbitol Alkyd ester; dimethoxane copolyol; polyglycerol ester, such as polyglyceryl-3-diisostearate; lauric acid glyceride; stearyl polyoxyethylene ether-2, stearyl alcohol Vinyl ether-10 and stearyl polyoxyethylene ether-20. Additional emulsifiers are provided in the INCI Ingredient Dictionary and Handbook, 11th Edition, 2006, the disclosure of which is incorporated herein by reference.

The emulsifiers may generally be present in an amount from about 0.001% to about 10% by weight, in one embodiment from about 0.01% to about 5% by weight, and in one embodiment from about 0.1% to about 3% by weight. In the composition.

The oil phase may comprise one or more volatile and/or non-volatile polyoxyphthalic oils. Volatile polyfluorene oxides include cyclic and linear volatile dimethyl oxa oxide polyoxyl. In one embodiment, the volatile polyoxo can include a cyclomethicone comprising tetramer (D ₄ ), pentamer (D ₅ ), and hexamer (D ₆ ) cyclomethine A siloxane or a mixture thereof. Mention may in particular be made of the volatile cyclomethicone-hexamethylcyclotrioxane, octamethyl-cyclotetraoxane and decamethyl-cyclopentaoxane. Suitable dimethoxane is commercially available from Dow Corning under the name Dow Corning 200® Fluid and has a viscosity in the range of from 0.65 to 600,000 centistokes or higher. Suitable non-polar, volatile liquid polyoxyxides are disclosed in U.S. Patent No. 4,781,917, the disclosure of which is incorporated herein in its entirety by reference. Other volatile polyoxo materials are described in Todd et al., "Volatile Silicone Fluids for Cosmetics", Cosmetics and Toiletries, 91: 27-32 (1976), the entire disclosure of which is incorporated herein by reference. Linear volatile polyoxyxene typically has a viscosity of less than about 5 centistokes at 25 °C, while cyclic polyfluorene has a viscosity of less than about 10 centistokes at 25 °C. Examples of volatile polyoxins of various viscosities include Dow Corning 200, Dow Corning 244, Dow Corning 245, Dow Corning 344, and Dow Corning 345 (Dow Corning); SF-1204 and SF-1202 Silicone Fluids (GE Silicones), GE 7207 and 7158 (General Electric); and SWS-03314 (SWS Silicones). Linear volatile polyoxymethylene includes low molecular weight polydimethyl methoxy hydride compounds, for example (only a few examples) hexamethyldioxane, octamethyltrioxane, decamethyltetraoxane And dodecamethylpentaoxane.

Non-volatile polyoxyxides typically comprise a polyalkyl siloxane, a polyaryl siloxane, a polyalkylaryl oxane or a mixture thereof. Polydimethylsiloxane is preferably a non-volatile polyoxyxene oil. The viscosity of the non-volatile polyoxyxene oil at 25 ° C can generally range from about 10 PCT Stokes to about 60,000 PCT Stokes, and in one embodiment between about 10 PCT Stokes and about 10,000 cc. Between the toxes, and still more preferably between about 10 centistokes and about 500 centistokes; and having a boiling point above 250 °C at atmospheric pressure. Non-limiting examples include dimethyl polyoxyalkylene (dimethyl polyoxyalkylene), phenyl trimethyl polyoxyalkylene, and diphenyl dimethyl polyoxyalkylene. Volatile and non-volatile polyoxyxides may optionally be subjected to various functional groups (for example, to name a few) alkyl, aryl, amine, vinyl, hydroxy, haloalkyl, alkylaryl and acrylate groups. Replaced by the regiment).

Nonionic surfactants (emulsifiers) may be utilized (e.g., polydiorganotoxioxane-polyoxyalkylene alkyl block copolymers, including those described in U.S. Patent No. 4,122,029, the disclosure of which is incorporated herein by reference. The manner of incorporation herein is an emulsified polyoxynionic water-in-water emulsion. The emulsifiers generally comprise a polydiorganotoxioxane skeleton having a side chain comprising -(EO)m- and/or -(PO)n- groups, typically polydimethyloxane, wherein the EO stretching Ethoxy and PO are 1,2-propenoxy, and the side chain is typically terminated or terminated by hydrogen or a lower alkyl group (e.g., _C1-6 , typically _C1-3 ). Other suitable polyoxynium emulsifiable emulsifiers are disclosed in U.S. Patent No. 6,685,952, the disclosure of which is incorporated herein by reference. Commercially available polyoxynized water emulsifiers include those available from Dow Corning under the trade names 3225C and 5225C FORMULATION AID, SILICONE SF-1528 available from General Electric, and from Goldschmidt Chemical Company (Hopewell, Va.). ABIL EM 90 and EM 97 and SILWET series emulsifiers sold by OSI Specialties (Danbury, Conn.).

Examples of polyoxynegated water emulsifiers include, but are not limited to, dimethoxane PEG 10/15 crosslinked polymer, dimethicone copolyol, cetyl dimethoxane copolymer Alcohol, PEG-15 lauryl dimethoxane cross-linked polymer, lauryl polyoxymethane Crosslinked polymer, cyclomethicone and dimethoxane copolyol, dimethoxane copolyol (and) caprylic/capric triglyceride, polyglycerol-4 isostearate (and) cetyl dimethoxane copolyol (and) hexyl laurate, and dimethyl polyoxyn copoly alcohol (and) cyclopentaoxane. Preferred examples of polyoxyxyl alcohol emulsifiers include, but are not limited to, PEG/PPG-18/18 dimethylpolyoxane (trade name 5225C, Dow Corning), PEG/PPG-19/19 dimethyl hydrazine. Oxyalkane (trade name BY25-337, Dow Corning), cetyl PEG/PPG-10/1 dimethylpolyoxane (trade name Abil EM-90, Goldschmidt Chemical), PEG-12 dimethyl fluorene Oxyalkane (trade name SF 1288, General Electric), lauryl PEG/PPG-18/18 fluorenone (trade name 5200 FORMULATION AID, Dow Corning), PEG-12 dimethylpolyoxane cross-linked polymer (trade name) 9010 and 9011 polyoxyxene elastomer blends, Dow Corning), PEG-10 dimethylpolyoxyalkylene crosspolymer (trade name KSG-20, Shin-Etsu), dimethylpolyoxane PEG-10 /15 crosslinked polymer (trade name KSG-210, Shin-Etsu) and dimethoxane PEG-7 isostearate.

The polyoxynoxa emulsifiable emulsifier can generally be present in an amount from about 0.001% to about 10% by weight, in one embodiment from about 0.01% to about 5% by weight, and in one embodiment from less than 1% by weight. The amount is present in the composition.

The aqueous phase of the emulsion can include one or more other solvents, including lower alcohols such as ethanol, isopropanol, and the like. The volatile solvent may also be a cosmetically acceptable ester such as butyl acetate or ethyl acetate; a ketone such as acetone or ethyl methyl ketone; or the like.

The oil-containing phase can generally comprise from about 10% to about 99% by weight, in one embodiment from about 20% to about 85% by weight, and in one embodiment from about 30% to about 70% by weight, based on the total weight of the emulsion. And the aqueous phase can generally comprise from about 1% to about 90% by weight of the total emulsion, in one embodiment from about 5% to about 70% by weight, and more often from about 20% to about 60 in one embodiment. weight%. The aqueous phase can generally comprise from about 25% to about 100% by weight, more typically from about 50% to about 95% by weight water.

The composition can include liposomes. Liposomes may contain other additives or substances and/or may It is modified to arrive or remain more specifically at the site after administration.

The recommended daily dose in accordance with the present invention ranges from 0.5 mg/day to 2600 mg/day and in one embodiment from 5 mg/day to 1200 mg/day of the osmanthus extract. The compositions of the invention may be administered for several days, weeks or months. The treatment regimen can be repeated multiple times a year and can even be continuous.

In one embodiment, the composition is intended for use as a non-therapeutic treatment. In another embodiment, the composition is intended to be wiped, poured, sprayed or sprayed onto the human body, introduced into the human body, or otherwise applied to the human body for cleaning, beautification, promotion, according to the US FD&C Act, sec. 201(i). An object that appeals or changes its appearance.

The compositions may optionally include other cosmetic actives and excipients which are apparent to those skilled in the art including, but not limited to, fillers, emulsifiers, antioxidants, surfactants, film formers, chelating agents. Mixture, gelling agent, thickener, emollient, moisturizer, moisturizer, vitamin, mineral, viscosity and / or rheology modifier, sunscreen, exfoliating agent, pigment loss agent, retinoid , hormone compound, α-hydroxy acid, α-keto acid, antimycobacterial agent, antifungal agent, antimicrobial agent, antiviral agent, analgesic, lipid compound, antiallergic agent, H1 or H2 antihistamine , anti-inflammatory, anti-irritant, anti-tumor, immune system enhancer, immune system inhibitor, acne, anesthetic, antiseptics, insect repellent, skin care, skin care, skin penetration enhancer , sanding agents, lubricants, fragrances, colorants, pigment loss agents, pigment lightening agents, preservatives (for example, DMDM caprolactam / iodopropynyl butyl carbonate), stabilizers, pharmaceutical agents , light stabilizer, neutralizer (example , Triethanolamine) and mixtures thereof. In addition to the above, the cosmetic composition of the present invention may also contain any other compound for treating a skin condition.

The compositions may contain other active ingredients with anti-aging benefits, as may be expected to achieve synergistic improvements using such combinations. Exemplary anti-aging components include, but are not limited to, a few examples of botanicals (eg, Butea Frondosa extract); thiodipropionic acid (TDPA) and its esters; retinoids (eg, total anti- Retinoic acid, 9-cis retinoic acid, phytanic acid and others); hydroxy acids (including alpha-hydroxy acids and beta-hydroxy acids), salicylic acid and salicylates; exfoliating agents (eg, ethanol) Acid, 3,6,9-trioxadecanedioic acid, etc.; estrogen synthase stimulating compounds (such as caffeine and derivatives); compounds capable of inhibiting 5α-reductase activity (eg, linoleic acid) , linoleic acid, finasteride and mixtures thereof; barrier function enhancers (eg, neuropterin, glycerol, cholesterol and its esters, alpha-hydroxy and ω-hydroxy fatty acids and their esters, etc.); collagen Enzyme inhibitors; and elastase inhibitors.

Compositions of the invention may also include skin lightening agents. Some examples of such suitable skin lightening agents include, but are not limited to, one or more of the following: ascorbyl glucoside, vitamin C, retinol and/or its derivatives, arbutin, bearberry extract , rumex crispus extract, milk protein (including hydrolyzed milk protein), N, N, S-叁 (carboxymethyl) cysteamine, oleanolic acids, perilla oil, placenta Extract, Saxifragia sarmentosa , Perilla extract, juniperic acid, TDPA, Ligusticum chiangxiong hart. , Asmunda japonica thunb. , Stellaria medica (L.) cyr .), Sedum sarmentosum bunge , Ligusticum lucidum Ait. , ilex purpurea hassk , emblica, apigenin, ascorbyl palmitol, long bean ( Carruba) polyphenols, hesperitin, inabata polyphenols, isoliquirtigenin, kaempferol-7-neohesperidose, L-mimosine (L) -mimosine), luteolin, oil-soluble licorice extract PT (40), oxa acid, phenyl isothiocyanate, cococin, silymarin, T4CA, tetrahydrocurcumin, unitrienol, bear AHA-oleanolic acid, UVA/URSI, hydroquinone, citric acid, Glycyrrhiza glabra , Chiarella vulgaris extract, coconut extract, butea frondosa , Naringi crenulata , Stenoloma chusana , Azadirachta indicia , Morinda citrifolia , or any combination thereof, see U.S. Patent No. 7,189,419, hereby incorporated by reference herein.

Suitable hydroxy acids include, for example, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, mandelic acid, salicylic acid, and alkyl derivatives thereof (including 5-n-octyl salicylic acid, 5-positive Dodecanedecyl salicylic acid, 5-n-decylsalicylic acid, 5-n-octylsalicylic acid, 5-n-heptyloxysalicylic acid, 4-n-heptyloxysalicylic acid) And 2-hydroxy-3-methylbenzoic acid or an alkoxy derivative thereof (for example 2-hydroxy-3-methoxybenzoic acid).

Exemplary retinoids include, but are not limited to, retinoic acid (eg, all-trans- or 13-cis) and derivatives thereof, retinol (vitamin A) and esters thereof (eg, retinyl palmitate, Retinol acetate and retinyl propionate) and salts thereof.

In another embodiment, the topical compositions of the present invention may also include one or more of the following: skin penetration enhancers, emollients, skin plumping agents, light scattering agents, sunscreens, exfoliating agents, and antioxidants.

Emollients provide functional benefits that enhance skin texture (smoothness) and reduce the appearance of fine lines and coarse wrinkles. Examples include isopropyl myristate, petrolatum, isopropyl lanolate, polyoxo (eg, polyoxyalkylene, dimethylpolyoxyalkylene), oils, mineral oils, fatty acid esters, Cetylethyl ethyl acrylate, C _12-15 alkyl benzoate, isopropyl isostearate, diisopropyl dimer dioleate or any mixture thereof. In one embodiment, the emollient may be present from about 0.1% to about 50% by weight of the total weight of the composition.

A skin fullness agent is used as a collagen enhancer for the skin. An example of a suitable and preferred skin plump agent is palmitoyl oligopeptide. Other skin plump agents are collagen and/or other glycosaminoglycan (GAG) enhancers. The skin plumping agent, if present, can comprise from about 0.1% to about 20% by weight of the total weight of the composition.

Light scattering agents are microparticles that alter the optical characteristics of the surface of the skin, which can cause blurred vision and soften, for example, lines and wrinkles. Examples of light scattering agents that can be used in the present invention include, but are not limited to: boron nitride, mica, nylon, polymethyl methacrylate (PMMA), poly Aurethane powder, sericite, cerium oxide, polyoxyn powder, talc, Teflon, titanium dioxide, zinc oxide or any mixture thereof. The light scattering agent, if present, can be present from about 0.01% to about 20% by weight of the total weight of the composition.

It can also include sunscreens that protect the skin from UV rays. Preferred sunscreens are those with extensive UVB and UVA protection, such as octyl cyanoacrylate, avobenzone (Parsol 1789), octyl methoxycinnamate, octyl salicylate, oxybenzone , trimethylcyclohexyl salicylate, benzophenone, camphor derivatives, zinc oxide and titanium dioxide. The sunscreen, if present, can comprise from about 0.01% to about 70% by weight of the composition.

Suitable exfoliating agents include, for example, alpha-hydroxy acids, beta-hydroxy acids, oxo acids, oxydiacids and derivatives thereof (e.g., esters, anhydrides, and salts thereof). Suitable hydroxy acids include, for example, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, mandelic acid, salicylic acid, and derivatives thereof. Another exfoliating agent is glycolic acid. The exfoliating agent, if present, can comprise from about 0.1% to about 80% by weight of the composition.

Antioxidants especially act to scavenge free radicals from the skin to protect the skin from environmental attack. Examples of the antioxidant which can be used in the composition of the present invention include compounds containing a phenolic hydroxyl functional group such as ascorbic acid and derivatives/esters thereof; ?-hydroxy acid; ?-carotene; catechol; curcumin; Wei acid derivatives (such as ethyl ferulate, sodium ferulate); gallic acid derivatives (such as propyl gallate); lycopene; reducing acid; rosmarinic acid; tannic acid; Tetrahydrocurcumin; tocopherol and its derivatives (eg, tocopheryl acetate); uric acid; or any mixture thereof. Other suitable antioxidants are those having one or more thiol functional groups (-SH) (in reduced or non-reduced form), such as glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds. The antioxidant may be an inorganic antioxidant such as bisulfite, metabisulfite, sulfite or other sulfur-containing inorganic salt and acid. The compositions of the present invention may comprise from about 0.001% to about 10% by weight, and in one embodiment from about 0.01% to about 5% by weight, of the total weight of the composition of the antioxidant.

In some embodiments, other actives may include collagen stimulating agents and/or elastin A stimulating agent (for example, a substance that stimulates elastin production) and/or a glycosaminoglycan enhancer. Examples of collagen, elastin, and glycosaminoglycan enhancers include, for example, fennel extract, carrot extract, and alfalfa extract. In some embodiments, other actives can include collagenase inhibitors and/or elastase inhibitors. In some embodiments, the present invention relates to the synergistic effect of one or more of the compositions described herein with perilla oil to, for example, provide enhanced anti-cellulite benefits to the skin.

In some embodiments, the cosmetic composition can further comprise at least one collagen and/or elastin irritant. Such collagen or elastin stimulators are effective, for example, to improve procollagen and/or collagen production and/or to improve the maintenance and remodeling of elastin.

Colorants can include, for example, organic and inorganic pigments and pearlizing agents. Suitable inorganic pigments include, but are not limited to, titanium oxide, zirconium oxide and cerium oxide, as well as zinc oxide, iron oxide, chromium oxide and ferrous blue. Suitable organic pigments include strontium, barium, calcium, aluminum lakes and carbon black. Suitable pearlescent agents include mica coated with titanium oxide, iron oxide or natural pigments.

Various fillers and other components can be added. The filler is typically present in an amount from about 0% to about 20% by weight, and in one embodiment from about 0.1% to about 10% by weight, based on the total weight of the composition. Suitable fillers include (but are not limited to) the following: silicon dioxide, treated silicon dioxide, talc, zinc stearate, mica, kaolin (Kaolin), nylon powder (e.g., Orgasol ^TM), polyethylene powder, Teflon ^TM, boron nitride, copolymer microspheres ^{(e.g., Expancel TM (Nobel Industries),} Polytrap TM (Dow Corning) and silicone polyethylene micro beads (from Toshiba of Tospearl ^TM)) and the like.

In one embodiment of the invention, the composition may include other skin actives such as, but not limited to, botanicals, exfoliating agents, peeling agents, keratinocyte proliferation enhancers, collagenase inhibitors, elastase inhibitors, pigments. Loss agents, anti-inflammatory agents, steroids, acne agents, antioxidants, salicylic acid or salicylates, anti-lipids, anti-cellulite agents, thiodipropionic acid and its esters, and advanced glycation end products (AGE) ) inhibitors.

In some embodiments, the cosmetic composition for combating signs of aging may further comprise an anti-lipid agent. For example, a cosmetic composition comprising a carnitine palmitoyltransferase-1 (CPT-1) stimulating agent (eg, an Averrhoa carambola leaf extract) in an amount effective to improve skin appearance may further comprise at least one other Anti-lipid agents, including one other anti-cellulite agent.

Exemplary anti-cellulite agents include, but are not limited to, phosphodiesterase inhibitors, such as xanthine analogs, caffeine, aminophylline, and theophylline; adenylate cyclase activators, For example, extracts of forskolin and Coleus forskohlii ; lipolytic stimulators such as hawthorn extract and cola extract; beta adrenergic receptor agonists such as isoproterenol; - adrenergic antagonists, such as yohimbine and ginkgo extract; perilla oil (see, for example, US 7,410,658); carnitine and/or creatine (see, for example, "Cosmetic Composition having Carnitine Creatinate and Methods" For use" and the entire contents of which is hereby incorporated by reference herein in its entirety.

In a particular embodiment, the composition may comprise at least one other botanical drug, such as a plant extract, an essential oil or the plant itself. Suitable botanicals include, but are not limited to, extracts from the following: Abies pindrow , Acacia catechu , Anogeissus latifolia , Asmunda japonica , Azadirachta Indica ), Butea frondosa , Butea monosperma , Cedrus deodara , Emblica officinalis , Ficus benghalensis , Licorice, French holly ( Ilex purpurea Hassk ), Sichuan Inula racemosa , Ligusticum chuangxiong , Ligusticum lucidum , Mallotus philippinensis , Mimusops elengi , eucalyptus , Moringa oleifera , Naringi crenulata ), Nerium indicum , Psoralea corylifolia , Fern, Terminalia bellerica , tomato glycolipid and mixtures thereof.

Other conventional additives include: vitamins such as tocopherol and ascorbic acid; vitamins Derivatives such as ascorbyl monopalmitate; thickeners such as hydroxyalkyl cellulose; gelling agents; structuring agents such as bentonite, bentonite, magnesium aluminum silicate and lithium magnesium niobate; Mixtures such as EDTA; pigments such as zinc oxide and titanium dioxide; colorants; emollients; and wetting agents.

In one embodiment, the composition is substantially free of components having strong oxidizing potential, including, for example, organic or inorganic peroxides. "Substantially free" of such components means that the amount present is not sufficient to have a measurable effect on the activity of the osmanthus extract. In some embodiments, this will be less than 1% by weight relative to the amount of osmanthus.

In one embodiment, the pH of the composition comprising the osmanthus extract of the present invention may be between about 1 and about 8. In certain embodiments, the pH of the composition will be acidic, i.e., less than 7.0, and in one embodiment may be between about 2 and about 7, and in one embodiment between about 3.5 and about 5.5.

Method of treating aging or aged skin

The present invention provides a method of treating aged skin by topically applying a composition comprising a osmanthus extract, in one embodiment, to a cosmetically acceptable vehicle, on the affected area. The period of time to reduce, ameliorate, reverse or prevent dermatological signs of aging. This method is especially useful for treating signs of skin photoaging and intrinsic aging.

Generally, the improvement in symptoms and/or aesthetics is selected from the group consisting of: dermatological signs that alleviate ageing, photoaging, hormonal aging, and/or actinic aging; prevention and/or reduction of streaks and/or The appearance of wrinkles; reduces facial lines and wrinkles, cheeks, facial wrinkles on the forehead, vertical wrinkles between the eyes, horizontal wrinkles above the eyes, and puppet lines around the mouth, and especially deep wrinkles or wrinkles Significant pleats; prevent, reduce and/or reduce the appearance and/or depth of creases and/or wrinkles; improve the appearance of underarms and/or around the eyelids; reduce the appearance of wrinkles around the eyes; restore and/or rejuvenate the skin , especially aging skin; reduce skin fragility; prevent and / or reverse the loss of glycosaminoglycan and / or collagen; improve female Effects of hormonal imbalance; prevention of skin atrophy; prevention, alleviation and/or treatment of hyperpigmentation; minimization of skin discoloration; improvement of skin tone, brilliance, transparency and/or firmness; prevention, reduction and/or improvement of sagging skin; improvement Skin firmness, fullness, suppleness and/or softness; improve procollagen and/or collagen production; improve skin texture and/or promote skin rejuvenation; improve skin barrier repair and/or function; improve skin contour appearance; Skin radiance and/or brightness; minimize dermatological signs of fatigue and/or stress; resist environmental stress; replenish ingredients in the skin that are reduced by aging and/or menopause; improve circulation between skin cells; enhance cell proliferation And/or multiplication; enhancing components that are reduced by aging and/or menopause; improving communication between skin cells; increasing cell proliferation and/or reproduction; increasing skin cell metabolism decreased by aging and/or menopause; delaying cell aging; Improve skin moisturization; enhance skin thickness; increase skin elasticity and / or resilience; enhance shedding; improve microcirculation; reduce and / or prevent cellulite Formed; and any combination thereof.

In another embodiment, the invention provides a method of treating discoloration of the skin by topically applying a flower comprising an extract of osmanthus fragrans on the affected area, in one embodiment a cosmetically acceptable medium The composition of the agent is in a period of time sufficient to reduce, ameliorate, reverse or prevent discoloration of the skin. This method is especially useful for treating discoloration due to photoaging and intrinsic aging. In general, the symptoms of skin discoloration and/or aesthetic improvement are selected from the group consisting of bleaching hyperpigmented hair, skin, lips and/or nails; reducing age spots; making skin discoloration uniform or optimal; improving under the eyes The appearance of dark circles; treatment of melasma, chloasma, freckles, scars after burns and hyperpigmentation after injury; bleaching of scalp, legs, face and other areas where bleaching and color reduction are desired; reducing melanin production and / or bleached nail stains.

In certain embodiments, a composition comprising an extract of osmanthus fragrans may be applied to combat the side effects of various pharmaceuticals known to exacerbate the effects of aging on the skin (specifically, those known to discolor the skin). Such pharmaceuticals include, but are not limited to, antibiotics (sulfonamide and tetracycline), diuretics, non-steroidal anti-inflammatory drugs Drugs, analgesics, psychoactive drugs, oral contraceptives, antiepileptic drugs (hydantoin), chloroquine, DOPA therapy (levodopa), heavy metals (drugs containing arsenic, antimony, gold or silver) and / or chemotherapeutic agents (cyclophosphamide, 5-fluorouracil, doxorubicin, daunorubicin and bleomycin). The composition comprising the osmanthus extract can be applied before, simultaneously or after administration of the medicinal agent.

The composition is typically applied to the skin once, twice or three times daily as long as the desired anti-aging results are achieved. The treatment regimen can include administration once a day for at least one week, at least two weeks, at least four weeks, at least eight weeks, or at least twelve weeks. Chronic treatment options are also covered.

The composition comprising the osmanthus extract is applied topically to the "individual in need", which means an individual who benefits from a visual sign that reduces skin damage or aging. In a specific embodiment, the osmanthus extract is provided in a pharmaceutically, physiologically, cosmetically and dermatologically acceptable vehicle, diluent or carrier, wherein the composition is topically applied to the affected skin to effectively improve the skin. The amount of symptoms and aesthetic appearance remains in the affected area.

In one embodiment, a method of treating fine lines and wrinkles comprises topically applying a composition of the invention comprising an extract of osmanthus to the skin of an individual in need thereof, for example, to reduce the severity or prevent or inhibit the appearance of fine lines and/or wrinkles. The amount and duration of new fine lines and/or wrinkles are applied directly to the fine lines and/or wrinkles. By qualitatively examining the form of wrinkles (eg, number, depth, length, area, volume, and/or width of wrinkles per unit area of the skin), for example, by visual inspection or by, for example, microscopy or computer aided amounts The effect of the composition on the formation or appearance of fine lines and wrinkles was evaluated in quantitative amounts. This embodiment includes the treatment of wrinkles on the skin of the hands, arms, legs, neck, chest and face, including the forehead.

It is also contemplated that the compositions of the present invention can be used to topically apply the composition to thin skin of an individual in need thereof to treat thin skin. In some embodiments, the treatment is for thin skin of men, while other embodiments treat thin skin of premenopausal or postmenopausal women, which are believed to vary with the age of men and women, and specifically women of different life stages. The ground is thin. The method of the invention can be employed in a prophylactic manner against aging in patients including those who have not yet exhibited signs of skin aging, most commonly in individuals under the age of 25. This method can also reverse or treat signs of aging after performance, as is common in patients over 25 years of age.

Instance

The following examples are intended to illustrate the invention, but are not to be construed as limiting the scope of the invention.

Example 1 Preparation of Osmanthus fragrans Extract I. Preparation of purified plant extracts for new bioassay screening Extraction scheme

250 g of ground osmanthus flowers were collected and subsequently dried in an electric oven at 60 ° C for 2 or 3 days. The dried flowers were then added to 1 L of 50% aqueous ethanol (EtOHIH ₂ O 50-50 v/v; 3 x 4 volumes) in a vessel and extracted by shaking the vessel at 150 ° C for 12 h at 37 °C. This extraction was repeated three times to achieve a total of 3 L of extract. The total extract was then subjected to vacuum concentration using a rotary evaporator at a temperature of 40 ° C to 50 ° C until the volume was reduced to about 150 m. The concentrated fraction was then diluted to 1500 ml with pure water and allowed to stand at 4 ° C for 12 h (or longer) and then centrifuged to remove any residue. 1500 ml of the now clarified solution were treated twice with 750 ml of hexane in a separatory funnel and the organic layer was discarded. The dry content of the remaining homogeneous aqueous solution was confirmed by taking 150 ml of a homogeneous solution sample and lyophilizing the sample. The resulting powder was weighed and used to calculate the total amount of dry matter in the homogeneous solution. The resulting powder is then redissolved in water (about 100-150 ml) and brought together with the homogeneous solution. Subsequently, 10% by weight of activated carbon was added to the homogeneous solution, and about 1500 ml of the solution was about 17 g of activated carbon. The solution was then stirred at 50 ° C for 1 hour and then filtered on filter paper (type, manufacturer) and the procedure repeated. Next, the now clarified solution was fractionated by liquid-liquid extraction using water-saturated n-butanol. Saturated butanol was prepared by adding the same volume of water to butanol in a separatory funnel, and after mixing, the organic upper layer was collected and used for liquid/liquid extraction of the clear solution. About 2250 water-saturated butanol was prepared for 1500 ml of clear solution. The water-saturated butanol was divided into three 750 ml portions and each was used to treat the clear solution three times in a separatory funnel. The resulting organic layer (butanol extract) and the aqueous layer each passed through a separatory funnel were separately collected and collected. First, an equal volume of water was added to the pooled butanol extract and the solution was concentrated under vacuum in a rotary evaporator. When the distillation was stopped, an equal volume of water was added and the concentration was repeated. The concentration was repeated a third time and the resulting solution was lyophilized (first purified extract). Next, the aqueous layer produced by each flow through the separatory funnel was concentrated by vacuum on a rotary evaporator to remove butanol (the azeotropic boiling point was less than 100 ° C and the bath temperature was 60 ° C). When the distillation was stopped, the aqueous solution was lyophilized (second purified extract). The first and second extracts are then combined and weighed.

Extraction Scheme 2 (exemplary)

A certain amount (g) of the ground flower of the osmanthus fragrans can be collected and pulverized. Subsequently, refluxing extraction can be carried out using water of 8-10 times by weight of the pulverized flower at 100 ° C using methods known to those skilled in the art. This step can be repeated. The resulting extracts can be filtered and condensed using methods known to those skilled in the art, after which the extracts can be subjected to vacuum distillation under suitable conditions known to those skilled in the art. The extract can then be mixed with a suitable amount of dextrin and spray dried.

The above extraction process can be modified and adjusted, as described in the remainder of the specification, especially during amplification to a larger volume for production.

II. HPLC

The extract of the extraction scheme 1 was then characterized by high performance liquid chromatography. A sample size of about 5 mg/mL was dispensed into 25/75 MeOH/H2O and subjected to ultrasonic treatment. Characterization was performed on a Zorbax SBC-18 column (7.5 cm x 4.6 mm, 3.5 um particle size) and detection was achieved using a diode array UV absorbance of 260 nm, 300 nm, and 360 nm. The lines in Figure 1 are shown in ascending order and 260 nm. On the bottom. Operating conditions were flow rate 1.5 ml/min; temperature, 40 ° C; sample injection volume, 20 μL; and run time, 19 minutes. The mobile phase gradient used is as follows.

The HPLC characterization of the extract is shown in Figure 1. In one embodiment, the substantially isolated extraction composition of the present invention exhibits an HPLC profile substantially similar to the HPLC profile depicted in FIG.

Example 2 Skin biomarkers are up-regulated in vivo.

Test the ability of osmanthus plant extracts to upregulate key skin biomarkers in vivo. 20 healthy female white individuals aged 30-65 years with type II or III skin and mild to moderate photodamage were treated with ingredients for 3 weeks on the dorsal side of the forearm (3 x 24 in a row under a semi-occlusion) Hour patch). The test article and vehicle were applied at random at 5 sites on each forearm. Each individual was treated with 0.2% strength in propylene glycol/ethanol/H ₂ O (65:25:10) vehicle and vehicle control in the osmanthus extract. The dose was applied at 2 mg/cm ² . After treatment, a 2 mm punch biopsy was obtained from each treatment site and fixed in 10% buffer formalin. Tissue samples were then embedded in paraffin, sectioned (5 micron thickness), processed and stained for the following skin markers - total collagen (by Masson Trichrome), procollagen and hyaluronic acid binding protein (HABP). In addition, the thickness of the skin was evaluated. For each marker, the treated site and the vehicle site were compared to determine the difference in marker intensity. If the intensity of the marker in the treated site is higher relative to the control, it indicates an improvement in the biomarker. Table 2 shows the percentage of individuals with improved skin biomarkers tested after 3 weeks of treatment with osmanthus extract.

When applied topically to the skin in vivo, the plant extract of osmanthus fragrans up-regulates several biomarkers, such as thickening of the epidermis (42.9% of individuals appearing increased), collagen (55.9% of individuals exhibiting an increase), and procollagen (61.3% of individuals exhibiting an increase) And hyaluronic acid binding protein (63.9% of individuals showed an increase). Up-regulation of such biomarkers, which are reduced in aged skin, is believed to cause an improvement in the appearance of aged or aged skin.

Example 3 Evaluation of in vitro pigment inhibition activity.

B16 mouse melanoma cells (cell line: ATCC, catalog number: CRL-6475) were grown in DMEM in 96-well tissue culture treated dishes. Cells were exposed to dilution test material or vehicle control for 7 days. After the treatment period, the amount of the produced pigment was quantified in a medium using a spectrophotometer at 540 nm. The percent inhibition produced by the pigment of the test active was calculated relative to the vehicle control. Osmanthus fragrans (0.1%) inhibits pigment production in the range of about 0% to 20%.

Example 4 A. Exemplary anti-cellulite compositions

Cosmetic compositions comprising osmanthus extracts topically applied to the skin presented or at risk of presenting cellulite are provided in Table 3.

B. Exemplary anti-aging composition

Cosmetic compositions comprising osmanthus extracts topically applied to the skin presenting or at risk of presenting aged or aged skin are provided in Table 4.

C. Exemplary Brightening Composition

Cosmetic compositions comprising osmanthus extracts topically applied to the skin exhibiting hyperpigmentation signs are provided in Table 5.

It is believed that the compositions (the above anti-cellulite, anti-aging and skin lightening cosmetic compositions) are Effectively treating, reversing, ameliorating and/or preventing signs of aging, in particular, it is believed that the compositions respectively reduce the appearance of cellulite, wrinkles, lines and sagging skin and discoloration of the skin. The compositions of Tables 3 to 5 can be applied to the skin in need of treatment, which means skin requiring anti-cellulite, anti-aging or skin lightening benefits. The cosmetic composition can be applied directly to the skin in need of treatment.

Applying the cosmetic compositions to aged or discolored skin twice or three times a day, as long as the desired anti-aging or skin lightening results are achieved, including daily administration for at least one week, at least two weeks, at least four weeks, Treatment regimen for at least eight weeks or at least twelve weeks. Alternatively, exemplary cosmetic compositions can be used for long-term treatment of aged or discolored skin.

The entire contents of all of the references cited herein, including the patent application and the disclosure, are hereby incorporated by reference in entirety for all purposes in the same extent in In particular, and individually, all of its contents are hereby incorporated by reference in their entirety for all purposes. It will be appreciated by those skilled in the art that various modifications and changes can be made in the present invention without departing from the spirit and scope of the invention. The specific embodiments described herein are provided by way of example only, and the invention is limited by the scope of the accompanying claims and the scope of the equivalents.

Claims (12)

A non-therapeutic method for improving the aesthetic appearance of an aging skin in need thereof, comprising topically applying to the skin a cosmetically acceptable vehicle comprising a composition of Maesa japonica extract effective to impart an aesthetically pleasing amount of skin . The method of claim 1, wherein the improved aesthetic is selected from the group consisting of: (a) reducing fine lines or wrinkles, (b) reducing skin pore size, and (c) improving skin thickness, fullness, and/or tightness. (d) improving skin suppleness and/or softness; (e) improving skin tone, radiance and/or transparency; (f) improving procollagen and/or collagen production; (g) improving elastin (k) improving skin texture and/or promoting re-texturization; (i) improving skin barrier repair and/or function; (j) improving the appearance of skin contours; (k) restoring skin Gloss and/or brightness; (l) essential nutrients and/or ingredients to replenish skin; (m) improve skin appearance attenuated by aging and/or menopause; (n) improve skin moistness and/or hydration; (o) Increase loss of skin elasticity and/or resilience; (p) reduce skin sagging; (q) reduce skin discoloration; and any combination thereof. The method of claim 1, wherein the skin is sensitive to the skin. The method of claim 1, wherein at least one of the compositions is topically applied at least once a day. week. The method of claim 1, wherein the extract is present in an amount of from 0.0001% by weight to 90% by weight based on the total weight of the composition. The method of claim 5, wherein the extract is present in an amount from 0.01% to 10% by weight based on the total weight of the composition. The method of claim 1, wherein the osmanthus plant extract is derived from the flower of the osmanthus plant. The method of claim 1 or 2, wherein the skin improvement is due to an increase in collagen synthesis, an increase in hyaluronic acid synthesis, an increase in epidermal thickness, a decrease in melanin synthesis, or any combination thereof. The method of claim 1, wherein the improving aesthetics is a luminous benefit. The method of claim 9, wherein the luminous benefit is selected from the group consisting of: (a) bleaching hyperpigmented hair, skin, lips and/or nails; (b) reducing age spots; (c) discoloring the skin Uniform or optimized; (d) improve the appearance of the dark circles under the eyes; (e) treat melasma, chollas, freckles, scars after burns and hyperpigmentation after injury; (f) bleaching scalp , hair on the legs, face and other areas where bleaching and color reduction are desired; (g) bleaching nail staining; and combinations thereof. The method of claim 9, wherein the luminous benefit is reduced due to melanin synthesis. The method of claim 1, comprising locally applying an effective amount of a scented osmanthus extract to the skin area in need thereof, wherein the osmanthus extract has the ability to modulate the skin biomarker by measuring the following Analysis of the amount of change in skin biomarkers in the group: thickening of the epidermis, total collagen, procollagen, and The hyaluronic acid binding protein in the body before the differentiation of the skin cells and/or skin cells that have been in contact with the osmanthus extract.